Valneva must immediately cease U.S. shipments and sales of Ixchiq, a vaccine for chikungunya virus. The FDA recently lifted a pause on dosing of Ixchiq, but the agency’s new safety alert is based on an assessment that found the vaccine appears to be causing chikungunya-like illness in recipients.

The United States Food and Drug Administration (FDA) has suspended the license for Valneva's chikungunya vaccine Ixchiq with immediate effect, the French drugmaker said on Monday. Valneva said the suspension follows four reports of serious adverse events consistent with the disease,

The FDA suspended Valneva’s U.S. license for its chikungunya vaccine Ixchiq due to serious safety concerns, multiple hospitalizations, and deaths linked to chikungunya-like illness.